Why Greenfire
How we build success
Medical innovations are precious and exciting and come from all over. Making a good idea in medicine into a product is a difficult and expensive process. It requires expertise and capital often not available for startups completing laboratory proof-of-concept.
That’s where Greenfire comes in. We have assembled experts, advisors, service providers, and capital to deploy on late pre-clinical and early clinical assets to accelerate their development into products.
Our extensive network seeks out exciting innovations, engages flexibly with the innovators, and accelerates the transition to medical products. We take the unappreciated risks out of development – timely access to expertise and capital. If you think you have an innovation that fits our profile, contact us.
And when a product is ready for the last steps for approval and commercialization, our team has deep experience in navigating the right path to optimize success and return for all participants.
Opportunity Access
Capitalize on access to innovative preclinical and early-stage clinical products and technology
Development Acceleration
Leverage an integrated ecosystem of development organizations and internal expertise to accelerate product development timelines
Business MONETIZATION
Monetize investments through strategic and well-timed out-licensing, sale or IPO of each product to provide liquidity to investors and the best path to bringing products to patients
Our process sounds simple but execution is where we excel
Acquire pipeline of differentiated products to meet underserved medical needs. If you think you have an innovation that fits our profile, contact us.
Deploy very experienced biopharma team for efficient drug development and business management
Utilize a successful organizational model; leverage virtual operations focused program management and partner ecosystem of service providers
Exit programs after advancing candidates to an appropriate value inflection point
Provide excellent returns to investors by delivering superior products to patients
MANAGEMENT TEAM
Ajit Gill
CEO and Founder, Director
CEO & President Nektar Therapeutics
VP and Gen Mgr Kodak’s Interactive Systems
VP Finance at TRW-Fujitsu
Steve Morris, MD
Head, Scientific Advisory Board
CEO & Internist/Medical Oncologist
Former PI: St Jude’s (discovered ALK, developed ALK CDx and inhibitors)
Michael Weickert, PhD
COO
CEO at Pacylex, Sonescence, SEA Med., COO Therashock, drug development at Ligand, Nektar, Auspex, NIH / NCI
Sanjeev Munshi, PHD, MBA
CBO
SVP, BD & Alliance Management, InveniAI
Ex. Director Merck BD and Discovery
Shailaja Gupta,PhD
Executive Director, CMC
Vikas Agarwal, PhD
VP Program Management
Gayathri Swaminath, PHD, MBA
VP Research
BOARD OF DIRECTORS
Purnanand Sarma, PhD
CEO Immunome
CEO Taris
GM Cephalon
VP Nektar
Ajit Gill
Director
Chris Searcy, Chief Corporate Development Officer
CBO Nocion
CBO Respira
CBO Taris
VP Valeritas, Nektar, Pfizer
Hong-Min Suh
Chair, M2N
CEO, DK Marine
Chair, The LEADCORP
Sang Hoon Shin
PIPELINE
Making a fast start to building an innovative pipeline, agnostic to therapeutic areas, we are addressing serious unmet medical needs.
If you think you have an innovation that fits this portfolio, contact us.
*Click for more information about portfolio candidates
| Product | Company | Target | Indication | Therapeutic Area | Discovery | Preclinical | Clinical | |||
|---|---|---|---|---|---|---|---|---|---|---|
| In Vitro | In vivo | Lead up | IND Enabling | Phase 1 | Phase 2 | |||||
| GRN-300 | Green3bio | SIK2/SIK3 inhibitor (First-in-Class) | Ovarian cancer, TNBC | Oncology | Q4 ‘23 Start | |||||
| PCLX-001 | Pacylex | NMT1, NMT2 inhibitor (First-in-class) | Diffuse Large B-Cell Lymphoma (DLBCL), Acute Myeloid Leukemia (AML) | Oncology | Q2 ‘23 Start | |||||
Questions? We’ve got answers!
Latest Articles
Green3Bio Announces Publication of Pre-Clinical Data Demonstrating SIK2 Inhibition (including GRN-300) Enhances PARP Inhibitor Activity Synergistically in Ovarian and Triple Negative Breast Cancers.
FRISCO, Texas, June 24, 2022 - PRNewswire Green3Bio, a subsidiary of Greenfire Bio, today announced a publication in the Journal of Clinical Investigation1 led by researchers at The University of Texas MD Anderson Cancer Center demonstrating that SIK2 inhibitors, including GRN-300 sensitized...
Greenfire Bio to update progress on Phase 1 Clinical Trial for SIK2/SIK3 inhibitor, GRN-300, in ovarian cancer at the ASCO Annual Meeting 2022
FRISCO, Texas, May 31, 2022 - PRNewswire Greenfire Bio, LLC announced today that its subsidiary, Green3Bio, and its collaborators at MD Anderson Cancer Center will present an update on the ongoing first-in-human clinical trial of GRN-300 at the upcoming ASCO 2022 Annual Meeting. GRN-300 is a...
Greenfire Bio Portfolio Company Pacylex Pharmaceuticals Initiates Phase 1 Clinical Study of PCLX-001 in Non-Hodgkin’s Lymphomas and Solid Tumor Cancer Patients
First clinical patient dosed at Cross Cancer Institute, Edmonton, Alberta, Canada Dallas, TX, September 14, 2021 Greenfire Bio portfolio company Pacylex Pharmaceuticals, Inc. announced today that it initiated a Phase 1 clinical trial of PCLX-001, a first-in-class, orally bioavailable small...